{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T10:43:15Z","timestamp":1760784195114,"version":"3.41.0"},"reference-count":107,"publisher":"Impact Journals, LLC","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2017,1,17]]},"DOI":"10.18632\/oncotarget.13484","type":"journal-article","created":{"date-parts":[[2016,11,22]],"date-time":"2016-11-22T02:14:20Z","timestamp":1479780860000},"page":"5578-5591","source":"Crossref","is-referenced-by-count":39,"title":["Mammographic density: a potential monitoring biomarker for adjuvant and preventative breast cancer endocrine therapies"],"prefix":"10.18632","volume":"8","author":[{"given":"Michael S.","family":"Shawky","sequence":"first","affiliation":[{"name":"Department of Head and Neck and Endocrine Surgery, Faculty of Medicine, University of Alexandria, Egypt"},{"name":"Department of Surgery, University College Hospital, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hilary","family":"Martin","sequence":"additional","affiliation":[{"name":"School of Medicine and Pharmacology, University of Western Australia, and Department of Medical Oncology, Fiona Stanley Hospital, Perth, Western Australia, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Honor J.","family":"Hugo","sequence":"additional","affiliation":[{"name":"Institute of Health and Biomedical Innovation and School of Biomedical Sciences, Queensland University of Technology, Australia"},{"name":"Translational Research Institute, Brisbane, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Lloyd","sequence":"additional","affiliation":[{"name":"Department of Radiology, Princess Alexandra Hospital, Brisbane, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kara L.","family":"Britt","sequence":"additional","affiliation":[{"name":"The Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia"},{"name":"Peter MacCallum Cancer Centre, Melbourne, Australia"},{"name":"Department of Anatomy and Developmental Biology, Monash University, Melbourne, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Redfern","sequence":"additional","affiliation":[{"name":"School of Medicine and Pharmacology, University of Western Australia, and Department of Medical Oncology, Fiona Stanley Hospital, Perth, Western Australia, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik W.","family":"Thompson","sequence":"additional","affiliation":[{"name":"Institute of Health and Biomedical Innovation and School of Biomedical Sciences, Queensland University of Technology, Australia"},{"name":"Translational Research Institute, Brisbane, Australia"},{"name":"Department of Surgery, University of Melbourne, St Vincent\u2019s Hospital, Melbourne, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2016,11,21]]},"reference":[{"volume-title":"Cancer Facts & Figures 2016","year":"2016","author":"American Cancer Society","key":"1"},{"key":"2","first-page":"3122","article-title":"Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline","author":"Ford","year":"2013","journal-title":"J Clin Oncol"},{"key":"3","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1200\/JCO.2013.54.2258","article-title":"Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update","volume":"32","author":"Griggs","year":"2014","journal-title":"J Clin Oncol"},{"key":"4","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1200\/JCO.2013.53.9411","article-title":"Interpreting Plasma Estrogen Levels in Breast Cancer: Caution Needed","volume":"32","author":"Dowsett","year":"2014","journal-title":"J Clin Oncol"},{"issue":"Suppl 2","key":"5","first-page":"S38","article-title":"Sex hormones and breast cancer risk and prognosis","volume":"22","author":"Dowsett","year":"2013","journal-title":"Breast"},{"key":"6","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S1470-2045(14)71171-4","article-title":"Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial","volume":"16","author":"Forbes","year":"2015","journal-title":"Lancet Oncol"},{"key":"7","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S0140-6736(13)62292-8","article-title":"Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial","volume":"383","author":"Howell","year":"2014","journal-title":"Lancet"},{"key":"8","doi-asserted-by":"crossref","unstructured":"Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005; 365:1687\u2013717.","DOI":"10.1016\/S0140-6736(05)66544-0"},{"key":"9","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s10549-014-2901-2","article-title":"Mammographic density-a review on the current understanding of its association with breast cancer","volume":"144","author":"Thompson","year":"2014","journal-title":"Breast Cancer Res Treat"},{"key":"10","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S0960-9776(03)00144-9","article-title":"Epidemiology of breast cancer - Selected highlights","volume":"12","author":"Cuzick","year":"2003","journal-title":"Breast"},{"key":"11","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1158\/1055-9965.EPI-05-0689","article-title":"Mammographic density correlation with Gail model breast cancer risk estimates and component risk factors","volume":"15","author":"McTiernan","year":"2006","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"12","doi-asserted-by":"crossref","first-page":"337","DOI":"10.7326\/0003-4819-148-5-200803040-00004","article-title":"Using clinical factors and mammographic breast density to estimate breast cancer risk: development and validation of a new predictive model","volume":"148","author":"Kerlikowske","year":"2008","journal-title":"Ann Intern Med"},{"key":"13","doi-asserted-by":"crossref","first-page":"5780","DOI":"10.1002\/cncr.24638","article-title":"Mammographic density and the risk of breast cancer recurrence after breast-conserving surgery","volume":"115","author":"McCready","year":"2009","journal-title":"Cancer"},{"key":"14","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1093\/jnci\/dji279","article-title":"Estrogen-plus-progestin use and mammographic density in postmenopausal women: Women's Health Initiative randomized trial","volume":"97","author":"Hulka","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"15","doi-asserted-by":"crossref","first-page":"R76","DOI":"10.1186\/bcr3186","article-title":"Adiposity, hormone replacement therapy use and breast cancer risk by age and hormone receptor status: a large prospective cohort study","volume":"14","author":"Teucher","year":"2012","journal-title":"Breast Cancer Res"},{"key":"16","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1093\/aje\/kwi286","article-title":"The association of endogenous sex steroids and sex steroid binding proteins with mammographic density: results from the Postmenopausal Estrogen\/Progestin Interventions Mammographic Density Study","volume":"162","author":"Reboussin","year":"2005","journal-title":"Am J Epidemiol"},{"key":"17","doi-asserted-by":"crossref","first-page":"e0128861","DOI":"10.1371\/journal.pone.0128861","article-title":"Breast Tissue Composition and Immunophenotype and Its Relationship with Mammographic Density in Women at High Risk of Breast Cancer","volume":"10","author":"Fox","year":"2015","journal-title":"PLoS One"},{"key":"18","doi-asserted-by":"crossref","unstructured":"Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001; 69:89\u201395.","DOI":"10.1067\/mcp.2001.113989"},{"key":"19","first-page":"39","article-title":"Prognostic and predictive markers for the new immunotherapies","volume":"28","author":"Atkins","year":"2014","journal-title":"Oncology (Williston Park, NY)"},{"key":"20","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1602\/neurorx.1.2.189","article-title":"Biomarkers and Surrogate Markers: An FDA Perspective","volume":"1","author":"Katz","year":"2004","journal-title":"NeuroRx"},{"key":"21","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1177\/1740774510368574","article-title":"Predictive biomarker validation in practice: lessons from real trials","volume":"7","author":"Sargent","year":"2010","journal-title":"Clin Trials"},{"key":"22","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1097\/01.SLA.0000059969.64262.87","article-title":"Rating the risk factors for breast cancer","volume":"237","author":"Singletary","year":"2003","journal-title":"Ann Surg"},{"key":"23","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1007\/s00268-013-2397-7","article-title":"Time to breast cancer relapse predicted by primary tumour characteristics, not lymph node involvement","volume":"38","author":"Walsh","year":"2014","journal-title":"World J Surg"},{"key":"24","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/978-3-319-22909-6","volume-title":"Novel Biomarkers in the Continuum of Breast Cancer","author":"Stearns","year":"2016"},{"key":"25","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1177\/030089160809400314","article-title":"Factors predictive of response to hormone therapy in breast cancer","volume":"94","author":"Crispino","year":"2008","journal-title":"Tumori"},{"key":"26","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1677\/erc.1.01095","article-title":"Stat5 expression predicts response to endocrine therapy and improves survival in estrogen receptor-positive breast cancer","volume":"13","author":"Iwase","year":"2006","journal-title":"Endocr Relat Cancer"},{"key":"27","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1093\/jnci\/djh106","article-title":"Tamoxifen and breast density in women at increased risk of breast cancer","volume":"96","author":"Duffy","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"28","first-page":"911","article-title":"Tamoxifen and Mammographic Breast Densities","volume":"9","author":"Robert","year":"2000","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"29","first-page":"917","article-title":"Effect of Tamoxifen on Mammographic Density","volume":"9","author":"Zujewski","year":"2000","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"30","first-page":"598","article-title":"Tamoxifen in women with breast cancer and mammographic density","volume":"29","author":"De Felice","year":"2008","journal-title":"Eur J Gynaecol Oncol"},{"key":"31","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0899-7071(01)00329-1","article-title":"Can tamoxifen cause a significant mammographic density change in breast parenchyma?","volume":"25","author":"Reaven","year":"2001","journal-title":"Clin Imaging"},{"key":"32","doi-asserted-by":"crossref","first-page":"3424","DOI":"10.1158\/1538-7445.AM2016-3424","article-title":"Longitudinal changes in volumetric breast density with adjuvant endocrine therapy among women with breast cancer","volume":"76","author":"Hruska","year":"2016","journal-title":"Cancer Res"},{"key":"33","first-page":"5","article-title":"Abstract P5-12-01: Predicting the effect of tamoxifen on the breast: Change in measures of breast density, serum markers and SNPs","volume":"75","author":"Cuzick","year":"2015","journal-title":"Cancer Res"},{"key":"34","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/GME.0b013e318271f5e7","article-title":"Breast density changes in a randomized controlled trial evaluating bazedoxifene\/conjugated estrogens","volume":"20","author":"Mirkin","year":"2013","journal-title":"Menopause"},{"key":"35","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1097\/GME.0b013e318199d07f","article-title":"Low-dose transdermal estradiol induces breast density and heterogeneity changes comparable to those of raloxifene","volume":"16","author":"Christiansen","year":"2009","journal-title":"Menopause"},{"key":"36","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1111\/j.1471-0528.2008.01690.x","article-title":"Differential impact of conventional and low-dose oral hormone therapy, tibolone and raloxifene on mammographic breast density, assessed by an automated quantitative method","volume":"115","author":"Sandset","year":"2008","journal-title":"BJOG"},{"key":"37","first-page":"177","article-title":"Does raloxifene therapy affect mammographic breast cancer screening in postmenopausal patients?","volume":"27","author":"Yucebilgin","year":"2006","journal-title":"Eur J Gynaecol Oncol"},{"key":"38","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1097\/00042192-200203000-00005","article-title":"Mammographic changes associated with raloxifene and tibolone therapy in postmenopausal women: A prospective study","volume":"9","author":"Creatsas","year":"2002","journal-title":"Menopause"},{"key":"39","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1093\/jnci\/93.1.51","article-title":"Digitized mammography: a clinical trial of postmenopausal women randomly assigned to receive raloxifene, estrogen, or placebo","volume":"93","author":"Zeng","year":"2001","journal-title":"J Natl Cancer Inst"},{"key":"40","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1158\/1055-9965.EPI-07-2752","article-title":"Effect of raloxifene on mammographic density and breast magnetic resonance imaging in premenopausal women at increased risk for breast cancer","volume":"17","author":"Prindiville","year":"2008","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"41","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1158\/1940-6207.CAPR-10-0076","article-title":"Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer","volume":"3","author":"James","year":"2010","journal-title":"Cancer Prev Res (Phila)"},{"key":"42","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1056\/NEJMoa1103507","article-title":"Exemestane for breast-cancer prevention in postmenopausal women","volume":"364","author":"Garber","year":"2011","journal-title":"N Engl J Med"},{"key":"43","first-page":"1327","article-title":"A pilot study of letrozole for one year in women at enhanced risk of developing breast cancer: effects on mammographic density","volume":"32","author":"Muggia","year":"2012","journal-title":"Anticancer Res"},{"key":"44","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1158\/1940-6207.CAPR-15-0269","article-title":"Exemestane Use in Postmenopausal Women at High Risk for Invasive Breast Cancer: Evaluating Biomarkers of Efficacy and Safety","volume":"9","author":"Eng-Wong","year":"2016","journal-title":"Cancer Prev Res (Phila)"},{"key":"45","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.breast.2006.10.007","article-title":"Pilot study of the impact of letrozole vs. placebo on breast density in women completing 5 years of tamoxifen","volume":"16","author":"Goss","year":"2007","journal-title":"Breast"},{"key":"46","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s10549-009-0662-0","article-title":"A randomized, placebo-controlled trial (NCIC CTG MAP1) examining the effects of letrozole on mammographic breast density and other end organs in postmenopausal women","volume":"120","author":"Goss","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"47","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s10549-010-1322-0","article-title":"A randomized, placebo-controlled trial (NCIC CTG MAP.2) examining the effects of exemestane on mammographic breast density, bone density, markers of bone metabolism and serum lipid levels in postmenopausal women","volume":"126","author":"Tu","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"48","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1093\/jnci\/djr079","article-title":"Tamoxifen-induced reduction in mammographic density and breast cancer risk reduction: a nested case-control study","volume":"103","author":"Warren","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"49","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1158\/0008-5472.SABCS-61","article-title":"Change in breast density as a biomarker of breast cancer risk reduction; results from IBIS-1","volume":"69","author":"Duffy","year":"2009","journal-title":"Cancer Res"},{"key":"50","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ijrobp.2008.04.007","article-title":"High mammographic breast density is independent predictor of local but not distant recurrence after lumpectomy and radiotherapy for invasive breast cancer","volume":"73","author":"Kerlikowske","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"51","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1158\/1538-7445.AM2013-2286","article-title":"Abstract 2286: Short term reduction in mammographic density predicts survival in breast cancer","volume":"73","author":"Baumgartner","year":"2013","journal-title":"Cancer Res"},{"key":"52","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1158\/1055-9965.EPI-10-0769","article-title":"Mammographic density and risk of second breast cancer after ductal carcinoma in situ","volume":"19","author":"Quesenberry","year":"2010","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"53","first-page":"107","article-title":"Prognostic significance of mammographic density change after initiation of tamoxifen for ER-positive breast cancer","author":"Gierach","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"54","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1200\/JCO.2012.44.5015","article-title":"Mammographic density reduction is a prognostic marker of response to adjuvant tamoxifen therapy in postmenopausal patients with breast cancer","volume":"31","author":"Hall","year":"2013","journal-title":"J Clin Oncol"},{"key":"55","doi-asserted-by":"crossref","first-page":"R57","DOI":"10.1186\/bcr3451","article-title":"Change of mammographic density predicts the risk of contralateral breast cancer - a case-control study","volume":"15","author":"Czene","year":"2013","journal-title":"Breast Cancer Res"},{"key":"56","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s10549-013-2726-4","article-title":"Adjuvant tamoxifen-induced mammographic breast density reduction as a predictor for recurrence in estrogen receptor-positive premenopausal breast cancer patients","volume":"142","author":"Lee","year":"2013","journal-title":"Breast Cancer Res Treat"},{"key":"57","doi-asserted-by":"crossref","first-page":"R102","DOI":"10.1186\/bcr3221","article-title":"Breast density change as a predictive surrogate for response to adjuvant endocrine therapy in hormone receptor positive breast cancer","volume":"14","author":"Moon","year":"2012","journal-title":"Breast Cancer Res"},{"key":"58","article-title":"Mammographic breast density as a predictor of hormone receptor positive breast cancer recurrence: A single centre longitudinal analysis","author":"Redfern","year":"2015","journal-title":"PD1-06 SABCS"},{"key":"59","doi-asserted-by":"crossref","first-page":"349","DOI":"10.3109\/0284186X.2014.964809","article-title":"Minimal impact of adjuvant exemestane or tamoxifen treatment on mammographic breast density in postmenopausal breast cancer patients: a Dutch TEAM trial analysis","volume":"54","author":"van de Velde","year":"2015","journal-title":"Acta Oncol"},{"key":"60","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s40471-014-0018-0","article-title":"Breast density and breast cancer risk: understanding of biology and risk","volume":"1","author":"Tamimi","year":"2014","journal-title":"Curr Epidemiol Rep"},{"key":"61","doi-asserted-by":"crossref","first-page":"5303","DOI":"10.1038\/ncomms6303","article-title":"Genome-wide association study identifies multiple loci associated with both mammographic density and breast cancer risk","volume":"5","author":"Brown","year":"2014","journal-title":"Nat Commun"},{"key":"62","doi-asserted-by":"crossref","first-page":"R51","DOI":"10.1186\/bcr2340","article-title":"Sex steroid metabolism polymorphisms and mammographic density in pre- and early perimenopausal women","volume":"11","author":"Sinsheimer","year":"2009","journal-title":"Breast Cancer Res"},{"key":"63","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s13058-015-0591-2","article-title":"Identification of two novel mammographic density loci at 6Q25.1","volume":"17","author":"Czene","year":"2015","journal-title":"Breast Cancer Res"},{"key":"64","doi-asserted-by":"crossref","first-page":"4353","DOI":"10.1038\/onc.2011.627","article-title":"Targeting of the adaptor protein Tab2 as a novel approach to revert tamoxifen resistance in breast cancer cells","volume":"31","author":"De Bortoli","year":"2012","journal-title":"Oncogene"},{"key":"65","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3109\/13697137.2013.798271","article-title":"Does mammographic density reflect the expression of breast cancer markers?","volume":"16","author":"Diorio","year":"2013","journal-title":"Climacteric"},{"key":"66","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s10549-014-3169-2","article-title":"Effects of Tamoxifen and oestrogen on histology and radiographic density in high and low mammographic density human breast tissues maintained in murine tissue engineering chambers","volume":"148","author":"Thompson","year":"2014","journal-title":"Breast Cancer Res Treat"},{"key":"67","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13058-015-0592-1","article-title":"High mammographic density is associated with an increase in stromal collagen and immune cells within the mammary epithelium","volume":"17","author":"Thompson","year":"2015","journal-title":"Breast Cancer Res"},{"key":"68","doi-asserted-by":"crossref","first-page":"249","DOI":"10.4161\/cam.20567","article-title":"Why the stroma matters in breast cancer: insights into breast cancer patient outcomes through the examination of stromal biomarkers","volume":"6","author":"Keely","year":"2012","journal-title":"Cell Adh Migr"},{"key":"69","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1083\/jcb.130.1.227","article-title":"A targeted mutation at the known collagenase cleavage site in mouse type I collagen impairs tissue remodeling","volume":"130","author":"Jaenisch","year":"1995","journal-title":"J Cell Biol"},{"key":"70","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1480-9222-13-4","article-title":"Quantitative assessment of mammary gland density in rodents using digital image analysis","volume":"13","author":"Thompson","year":"2011","journal-title":"Biol Proced Online"},{"key":"71","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/bcr2942","article-title":"Mammographic density and breast cancer risk: current understanding and future prospects","volume":"13","author":"Minkin","year":"2011","journal-title":"Breast Cancer Res"},{"key":"72","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/S0140-6736(05)60503-X","article-title":"Tamoxifen in early breast cancer","volume":"352","author":"Onishi","year":"1998","journal-title":"Lancet"},{"key":"73","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1158\/2159-8290.CD-12-0107","article-title":"CD36 repression activates a multicellular stromal program shared by high mammographic density and tumor tissues","volume":"2","author":"Hu","year":"2012","journal-title":"Cancer discov"},{"key":"74","first-page":"S18","article-title":"Molecular mediators of mammographic density","volume":"237","author":"Jones","year":"2015","journal-title":"J Pathol"},{"key":"75","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s10911-007-9048-2","article-title":"Hedgehog signaling in mammary gland development and breast cancer","volume":"12","author":"Frost","year":"2007","journal-title":"J Mammary Gland Biol Neoplasia"},{"key":"76","first-page":"1021","article-title":"The pathobiology of mammographic density","volume":"2","author":"Thompson","year":"2014","journal-title":"J Cancer Biol Res"},{"key":"77","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/nrc1877","article-title":"Fibroblasts in cancer","volume":"6","author":"Zeisberg","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"78","first-page":"2606","article-title":"Tamoxifen interferes with the insulin-like growth factor I receptor (IGF-IR) signaling pathway in breast cancer cells","volume":"57","author":"Surmacz","year":"1997","journal-title":"Cancer Res"},{"key":"79","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/j.humpath.2004.09.005","article-title":"Expression of insulin-like growth factor 1 receptor in primary breast cancer: immunohistochemical analysis","volume":"35","author":"Fujiwara","year":"2004","journal-title":"Hum Pathol"},{"key":"80","doi-asserted-by":"crossref","first-page":"572","DOI":"10.3892\/mco.2015.497","article-title":"Insulin-like growth factor 1 receptor expression in breast cancer tissue and mammographic density","volume":"3","author":"Koo","year":"2015","journal-title":"Mol Clin Oncol"},{"key":"81","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/BF01833337","article-title":"Tamoxifen reduces serum insulin-like growth factor I (IGF-I)","volume":"22","author":"Lefebvre","year":"1992","journal-title":"Breast Cancer Res Treat"},{"key":"82","doi-asserted-by":"crossref","unstructured":"The Endogenous Hormones Breast Cancer Collaborative Group. Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies. Lancet Oncol. 2010; 11:530\u2013542.","DOI":"10.1016\/S1470-2045(10)70095-4"},{"key":"83","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1158\/1055-9965.EPI-06-0788","article-title":"Insulin-like growth factor and mammographic density in postmenopausal Norwegian women","volume":"16","author":"Gram","year":"2007","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"84","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s10549-015-3520-2","article-title":"Increased COX-2 expression in epithelial and stromal cells of high mammographic density tissues and in a xenograft model of mammographic density","volume":"153","author":"Thompson","year":"2015","journal-title":"Breast Cancer Res Treat"},{"key":"85","doi-asserted-by":"crossref","first-page":"225","DOI":"10.4142\/jvs.2015.16.2.225","article-title":"The potential role of COX-2 in cancer stem cell-mediated canine mammary tumor initiation: an immunohistochemical study","volume":"16","author":"Lin","year":"2015","journal-title":"J Vet Sci"},{"key":"86","doi-asserted-by":"crossref","first-page":"A32","DOI":"10.1158\/1940-6215.PREV-13-A32","article-title":"Abstract A32: Patterns of longitudinal change in mammographic density among tamoxifen users","volume":"6","author":"Gierach","year":"2013","journal-title":"Cancer Prev Res"},{"key":"87","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1158\/1055-9965.EPI-15-0412","article-title":"Longitudinal Change in Mammographic Density among ER-Positive Breast Cancer Patients Using Tamoxifen","volume":"25","author":"Gierach","year":"2016","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"88","doi-asserted-by":"crossref","first-page":"e50","DOI":"10.14694\/EdBook_AM.2015.35.e50","article-title":"Addressing barriers to uptake of breast cancer chemoprevention for patients and providers","author":"Crew","year":"2015","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"89","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1056\/NEJMoa1412379","article-title":"Adjuvant ovarian suppression in premenopausal breast cancer","volume":"372","author":"Geyer","year":"2015","journal-title":"N Engl J Med"},{"key":"90","doi-asserted-by":"crossref","first-page":"R93","DOI":"10.1186\/bcr3495","article-title":"Association of CYP2D6 metabolizer status with mammographic density change in response to tamoxifen treatment","volume":"15","author":"Hall","year":"2013","journal-title":"Breast Cancer Res"},{"key":"91","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2217\/pgs.13.221","article-title":"Association between CYP2D6 genotypes and the clinical outcomes of adjuvant tamoxifen for breast cancer: a meta-analysis","volume":"15","author":"Lim","year":"2014","journal-title":"Pharmacogenomics"},{"key":"92","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ctrv.2015.01.002","article-title":"Individualization of tamoxifen therapy: much more than just CYP2D6 genotyping","volume":"41","author":"van Gelder","year":"2015","journal-title":"Cancer Treat Rev"},{"key":"93","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.tranon.2015.10.002","article-title":"Imaging Breast Density: Established and Emerging Modalities","volume":"8","author":"Su","year":"2015","journal-title":"Transl Oncol"},{"key":"94","doi-asserted-by":"crossref","unstructured":"Al Kattar, El Balaa, Mazeh, Fakih, Shamas, Eldeen, Sleiman, Omayrat. 2015 International Conference on Advances in Biomedical Engineering (ICABME) 37-40 (IEEE, 2015).","DOI":"10.1109\/ICABME.2015.7323245"},{"key":"95","unstructured":"(The Mammography Quality Standards Act Final Regulations: Preparing For MQSA Inspections [ [Internet]. US Food and Drug Administration. 2001. [ [cited 2014 Jul 4])."},{"key":"96","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1148\/radiol.10100570","article-title":"Radiation doses and cancer risks from breast imaging Studies","volume":"257","author":"Hendrick","year":"2010","journal-title":"Radiology"},{"key":"97","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1200\/JCO.2005.02.9934","article-title":"Preliminary results on safety and activity of a randomized, double-blind, 2 \u00d7 2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in premenopausal women","volume":"24","author":"Johnson","year":"2006","journal-title":"J Clin Oncol"},{"volume-title":"Trial of Low Dose Tamoxifen in Women With Breast Intraepithelial Neoplasia (TAM-01).In:[Internet]","year":"2000","author":"Decensi","key":"98"},{"key":"99","doi-asserted-by":"crossref","first-page":"4201","DOI":"10.1200\/JCO.2006.09.4318","article-title":"Randomized dose-ranging trial of tamoxifen at low doses in hormone replacement therapy users","volume":"25","author":"Penotti","year":"2007","journal-title":"J Clin Oncol"},{"key":"100","unstructured":"University of Alabama at Birmingham. Low-Dose Tamoxifen Citrate in Reducing Breast Cancer Risk in Radiation-Induced Cancer Survivors (LDTam). In: ClinicalTrials.gov [Internet]. Bethesda (MD), National Library. of Medicine (US). 2000- [cited 2016 Feb 20]. Available from http:\/\/clinicaltrials.gov\/show\/NCT01196936. NLM Identifier: NCT01196936."},{"volume-title":"Letrozole in Preventing Breast Cancer in Postmenopausal Women","year":"2000","author":"Dana-Farber Cancer Institute","key":"101"},{"key":"102","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/jnci\/95.1.4","article-title":"Biological significance of interventions that change breast density","volume":"95","author":"McTiernan","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"103","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1007\/s12609-013-0116-x","article-title":"Biomarker Endpoints for Early-Phase Cancer-Prevention Studies","volume":"5","author":"Crew","year":"2013","journal-title":"Curr Breast Cancer Rep"},{"key":"104","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/sim.4780080407","article-title":"Surrogate endpoints in clinical trials: definition and operational criteria","volume":"8","author":"Prentice","year":"1989","journal-title":"Stat Med"},{"key":"105","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.maturitas.2009.07.009","article-title":"Hormone therapy, mammographic density, and breast cancer risk","volume":"64","author":"Boyd","year":"2009","journal-title":"Maturitas"},{"key":"106","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1093\/jnci\/djr115","article-title":"Tamoxifen, mammographic density, and breast cancer prevention","volume":"103","author":"Boyd","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"107","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/S1470-2045(11)70270-4","article-title":"Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years median follow-up","volume":"12","author":"Gelber","year":"2011","journal-title":"Lancet Oncol"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.13484","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T19:57:39Z","timestamp":1749758259000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.13484"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,21]]},"references-count":107,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,1,17]]}},"alternative-id":["13484","27894075"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.13484","relation":{},"ISSN":["1949-2553"],"issn-type":[{"type":"electronic","value":"1949-2553"}],"subject":[],"published":{"date-parts":[[2016,11,21]]}}}